– USA, NY – Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC), a special purpose acquisition company, today announced the nominees who will stand for election/reelection to its Board of Directors during the August 24, 2021, AHAC special shareholder’s meeting to vote on the proposed business combination with Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale.
On February 17, 2021, AHAC, a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
The post-combination Board will be comprised of 11 directors, including seven independent directors.
- Gordon Binder, former CEO of Amgen; Trustee of Massachusetts Institute of Technology and California Institute of Technology
- Emery Brown, M.D., Ph.D., Professor, Massachusetts Institute of Technology and Harvard University
- Mike Constantino, Director, 9 Meters Biopharma, Inc.; retired partner, Ernst & Young
- Todd Pope, CEO of WellAir; former CEO of TransEnterix and J&J Cordis
- Rajiv Shukla, Chairman, and CEO of Alpha Healthcare Acquisition Corp.
- Sue Windham-Bannister, Director, St. Jude Medical Center; past President, Massachusetts Life Sciences Center
- Laura Niklason, M.D., Ph.D., founder and CEO of Humacyte
- Kathleen Sebelius, former Secretary of the Department of Health and Human Services
- Brady Dougan, CEO of Exos Financial
- Max Wallace, JD, former CEO of Trimeris Inc.
- Jeffrey Lawson, M.D., Ph.D., Chief Surgical Officer of Humacyte
“Humacyte has an impressive platform and vision for producing revolutionary medical products for patients,” said Gordon Binder. “I am looking forward to participating in Humacyte’s Board and helping to guide the company through its next phase of growth.”
Rajiv Shukla commented “Humacyte has the potential to radically improve clinical care for patients and physicians across multiple indications while reducing overall costs for payors. I am excited to work with the Humacyte Board and Team to fulfill this vision.”
Subject to approval by the AHAC stockholders, the changes to the Board of Directors will be effective at the closing of the business combination between Humacyte and AHAC, expected in the third quarter of 2021.
“The post-merger Board composition will provide an important balance of continuity, along with expert commercial and financial perspectives, that will be invaluable as we enter the public markets,” said Dr. Laura Niklason. “We are grateful to all our current and future directors for their support of Humacyte’s universally implantable human tissues, which we believe will transform medicine and improve patient care.”
About Humacyte
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels, is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense.
For more information: https://humacyte.com/
About Alpha Healthcare Acquisition Corp.
Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed to effect a business combination with one or more businesses in the healthcare sector. The company was founded by Mr. Rajiv Shukla who has two decades of buyouts, investments, and operations experience in the healthcare industry. Mr. Shukla previously served as Chairman and CEO of Constellation Alpha Capital Corp., a Nasdaq-listed special purpose acquisition company, that merged with DermTech, Inc (ticker: DMTK) in August 2019. On February 17, 2021, AHAC announced a definitive agreement to merge with Humacyte, Inc. along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at $10.00 per share.
For more information: https://www.constellationalpha.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.